Assessment of the Effect of a Dermatology-Oriented Spa Therapy on the Quality of Life of Patients With Psoriasis
BAREGES
Assessment at 4.5 Months of the Effect of a Dermatology-Oriented Spa Therapy on the Quality of Life of Patients With Psoriasis (BAREGES)
1 other identifier
interventional
70
1 country
2
Brief Summary
Evaluation of the effect of a dermatology-oriented spa therapy at 4.5 months on the quality of life of patients suffering from psoriasis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2025
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 11, 2024
CompletedFirst Posted
Study publicly available on registry
December 16, 2024
CompletedStudy Start
First participant enrolled
April 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2028
May 13, 2025
May 1, 2025
1.2 years
December 11, 2024
May 12, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the effect of a complete thermal treatment (moderate impact) for a dermatological indication on the quality of life of patients with psoriasis
Percentage of patients with a score ≤ 10 (moderate impact) on the Dermatology Life Quality Index (DLQI) questionnaire at 4.5 months.The DLQI score is between 0 and 30 where a high score indicates a significant impairment of quality of life.
4.5 months
Secondary Outcomes (13)
To evaluate the effect of a complete thermal treatment (low impact) for a dermatological indication on the quality of life of patients with psoriasis at 4.5 months, taking into account all the care provided
4.5 months
To evaluate dermatology-specific quality of life (quantitative DLQI score)
4.5 and 9 months
To evaluate overall quality of life using the EQ-5D-5L questionnaire.
4.5 and 9 months
To evaluate the clinical improvement of psoriasis in the short and medium term.
4.5 and 9 months
To evaluate pain and pruritus.
4.5 and 9 months
- +8 more secondary outcomes
Study Arms (1)
Experimental: patient treated with a dermatology-oriented spa therapy
EXPERIMENTALThermal treatments among the following: Filiform shower, simple bath, aerated bath, general shower, compresses, nebulization inhalation, multiple local mud applications, and drinking cure.
Interventions
Thermal treatments among the following: Filiform shower, simple bath, aerated bath, general shower, compresses, nebulization inhalation, multiple local mud applications, and drinking cure.
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years Patient with psoriasis Stable treatment in the last 6 months. DLQI \> 10 Patient presenting an indication for thermal treatment focused on dermatology (possible dual orientation).
- Patient affiliated to the social security system or such a system Available for an 18-day spa treatment and a 9-month follow-up For women of childbearing age: effective contraception Patient information and informed consent signature
You may not qualify if:
- Contraindication to thermal treatment (e.g., ongoing chemotherapy/radiotherapy, uncontrolled progressive neoplasia, progressive heart disease, etc., according to the investigator's assessment) Predictable intolerance to thermal treatments (intolerance to heat, baths, etc.) Patient who has already undergone a dermatology-oriented spa treatment within the current thermal season Subject already included in an interventional clinical research protocol Persons referred to in articles L1121-5 to L1121-8 of the "Code de la Santé Publique" (pregnant women, women in labour and parturient and nursing mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure or not being able to verbally communicate their agreement, minor)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Thermes de Baregeslead
- Floraliscollaborator
- University Grenoble Alpscollaborator
Study Sites (2)
Centre Hospitalier Victor Dupouy
Argenteuil, 95107, France
Cabinet Luz Saint Sauveur
Pierrefitte-Nestalas, 65120, France
Related Publications (3)
Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998 Sep;39(3):464-75. doi: 10.1016/s0190-9622(98)70325-1.
PMID: 9738783BACKGROUNDSOLOMON WM, NETHERTON EW, NELSON PA, ZEITER WJ. Treatment of psoriasis with Goeckerman technic. Arch Phys Med Rehabil. 1955 Feb;36(2):74-7. No abstract available.
PMID: 13229486BACKGROUNDKazandjieva J, Grozdev I, Darlenski R, Tsankov N. Climatotherapy of psoriasis. Clin Dermatol. 2008 Sep-Oct;26(5):477-85. doi: 10.1016/j.clindermatol.2008.05.001.
PMID: 18755366BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 11, 2024
First Posted
December 16, 2024
Study Start
April 28, 2025
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
May 1, 2028
Last Updated
May 13, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share